Characterization of Arrhythmogenic Activity During and After Physical Exercise in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Current guidelines advocate that ARVC patients, typically young and active individuals with a significant history of competitive endurance sports, cease endurance training in favour of activities with low cardiac burden such as bowling and golf. Empirically, it is often suggested that heart rate during exercise should not exceed 100-120 bpm in these patients, but these guidelines are arbitrary and not scientifically based. In practice, it is estimated that up to 50% of patients do not comply with these recommendations . Adequate quantification of the arrhythmogenic burden, defined as premature ventricular beats in proportion to all heart beats in each period of time, and cardiac load (defined as stroke volume for volume load and systolic blood pressure for pressure load) experienced by ARVC patients when performing different types of physical exercise would be a first step towards designing a safe and effective intervention so that these patients can profit from an active life style. This study therefore aims to quantify and describe the arrhythmogenic burden and cardiac load experienced by patients with ARVC while performing different physical exercise over a range of intensities - all strictly within the range currently recommended by different cardiological societies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Definitive ARVC diagnosis according to the modified 2010 ARVC Task Force Criteria

• Pathogenic / likely pathogenic variant in one of the following desmosomal genes: plakophilin-2 (PKP-2), desmoglein-2 (DSG-2) or desmoplakin (DSP) or gene-elusive definite ARVC (i.e., genetic test performed but no pathogenic / likely pathogenic variant found)

• Agreement with responsible primary cardiologist that study participation is not considered beyond acceptable levels of physical activity for this particular patient

• No history of exercise-induced syncope in the 6 months prior to study participation

• No history of sudden cardiac arrest in the 6 months prior to study participation

• In patients who suffered from sudden cardiac arrest/arrhythmic syncope, only those having an implantable cardioverter-defibrillator (ICD) and being under beta-blockers/antiarrhythmic drugs are eligible for study inclusion

• Informed Consent as documented by signature (Appendix Informed Consent Form)

• Age: \> 18 years

• Body-Mass-Index (BMI): 18.5 - 29.9 kg・m-2

• Willing to adhere to the following study rules:

‣ No intense exercise 48h prior to testing

⁃ No exercise 24h prior to testing

⁃ Sleep at least 7h the two nights before testing On test day

⁃ No caffeinated food or drink before testing on test day

⁃ No alcohol before testing on test day

⁃ Fully compliant with normal medication regimen including beta-blockers and antiarrhythmic medication

Locations
Other Locations
Switzerland
Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich
RECRUITING
Zurich
Contact Information
Primary
Fernando G Beltrami, PhD
fernando.beltrami@hest.ethz.ch
+41446330472
Backup
Christina M Spengler, PhD, MD
spengler@ethz.ch
+41446325007
Time Frame
Start Date: 2023-08-01
Estimated Completion Date: 2025-08-31
Participants
Target number of participants: 64
Treatments
Experimental: Patients Group
All patients will perform all exercises. Arrhythmogenic activity will compared with that assessed during treadmill walking.
Related Therapeutic Areas
Sponsors
Leads: Swiss Federal Institute of Technology
Collaborators: University of Zurich

This content was sourced from clinicaltrials.gov